Next-Gen Sequencing of CSF Diagnoses Neurobrucellosis
By LabMedica International staff writers Posted on 21 Feb 2018 |
Image: The Agilent 2100 bioanalyzer is a distinctive analysis tool capable of handling cells, proteins and nucleic acids on a single platform (Photo courtesy of Agilent Technologies).
Brucellosis is the most common zoonotic infection in the world with more than 500,000 new cases are reported annually worldwide. It is a multisystem infection, with variable clinical presentations and brucellosis with nervous system involvement is known as Neurobrucellosis (NB).
The clinical features and cerebrospinal fluid (CSF) findings of NB are usually non-specific, and the sensitivity and specificity of routine culture and serological tests vary, making the diagnosis of NB difficult. In endemic areas, NB should be considered in the differential diagnosis of patients presenting with neurological symptoms and concomitant fever.
Scientists at the Peking Union Medical College Hospital (Beijing, China) and their colleagues studied a case series that included four consecutive patients admitted to the Neurology Department between June 1, 2016 and June 1, 2017. The demographic, clinical, radiological, and pathogenic findings, along with treatment and outcomes data, were extracted from the hospital information system.
The team used a 300-μL CSF sample from each patient or a negative ‘no-template’ control (NTC), which was transferred to a new sterile tube, and the DNA was extracted directly with the TIANamp Micro DNA Kit. Extracted DNA was used for the construction of DNA libraries. The DNA libraries were constructed according to the standard protocol of the BGISEQ-100 sequencing platform.
To measure the adapters before sequencing, quality control was performed with the Agilent 2100 Bioanalyzer combined with quantitative polymerase chain reaction (qPCR). Agarose gel electrophoresis was used to analyze the PCR products, and Sanger sequencing with an ABI PRISM 3730 DNA Analyzer was used to validate the sequencing results.
The four patients were rapidly diagnosed with NB using next-generation sequencing (NGS) of the CSF in patients with clinically suspected CNS infections, although the clinical manifestations varied dramatically between these patients. NGS of the CSF revealed that the sequence reads identified that corresponded to Brucella species ranged from 11 to 104, with genomic coverage ranging from 0.043% to 0.4%. Rapid diagnosis led to prompt treatment with the appropriate antibiotics. The authors concluded that their study demonstrated the power of NGS of the CSF coupled with a bioinformatic pipeline in the diagnosis of NB. The study was published in the February 2018 issue of the International Journal of Infectious Diseases.
Related Links:
Peking Union Medical College Hospital
The clinical features and cerebrospinal fluid (CSF) findings of NB are usually non-specific, and the sensitivity and specificity of routine culture and serological tests vary, making the diagnosis of NB difficult. In endemic areas, NB should be considered in the differential diagnosis of patients presenting with neurological symptoms and concomitant fever.
Scientists at the Peking Union Medical College Hospital (Beijing, China) and their colleagues studied a case series that included four consecutive patients admitted to the Neurology Department between June 1, 2016 and June 1, 2017. The demographic, clinical, radiological, and pathogenic findings, along with treatment and outcomes data, were extracted from the hospital information system.
The team used a 300-μL CSF sample from each patient or a negative ‘no-template’ control (NTC), which was transferred to a new sterile tube, and the DNA was extracted directly with the TIANamp Micro DNA Kit. Extracted DNA was used for the construction of DNA libraries. The DNA libraries were constructed according to the standard protocol of the BGISEQ-100 sequencing platform.
To measure the adapters before sequencing, quality control was performed with the Agilent 2100 Bioanalyzer combined with quantitative polymerase chain reaction (qPCR). Agarose gel electrophoresis was used to analyze the PCR products, and Sanger sequencing with an ABI PRISM 3730 DNA Analyzer was used to validate the sequencing results.
The four patients were rapidly diagnosed with NB using next-generation sequencing (NGS) of the CSF in patients with clinically suspected CNS infections, although the clinical manifestations varied dramatically between these patients. NGS of the CSF revealed that the sequence reads identified that corresponded to Brucella species ranged from 11 to 104, with genomic coverage ranging from 0.043% to 0.4%. Rapid diagnosis led to prompt treatment with the appropriate antibiotics. The authors concluded that their study demonstrated the power of NGS of the CSF coupled with a bioinformatic pipeline in the diagnosis of NB. The study was published in the February 2018 issue of the International Journal of Infectious Diseases.
Related Links:
Peking Union Medical College Hospital
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia